Latest Breaking News On - Immuno oncology congress - Page 4 : comparemela.com

Investegate announcements from F. Hoffmann-La Roche Ltd, New data from the phase II CITYSCAPE trial show encouraging results with Roche’s novel anti-TIGIT tiragolumab plus Tecentriq

United statesNathalie meetzSileia urechLevi garrawayLoren kalmKarsten kleineNational institutes of healthDrug administrationUs national library of medicineHead of global product developmentOncology congressRoche groupEuropean society for medical oncologyRoche group media relationsBreakthrough therapy designationProffered paper